Kura Oncology (NASDAQ:KURA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Kura Oncology, Inc. (NASDAQ:KURA) shares crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $9.81 and traded as low as $7.47. Kura Oncology shares last traded at $7.61, with a volume of 8,211,639 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KURA. Deutsche Bank Aktiengesellschaft set a $24.00 price target on Kura Oncology in a report on Wednesday, October 14th. Barclays set a $24.00 price objective on Kura Oncology in a research note on Wednesday, October 14th. Wedbush raised their price objective on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. started coverage on Kura Oncology in a research note on Thursday, October 1st. They set an “overweight” rating and a $30.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, October 14th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.35.

Kura Oncology Stock Up 6.9%

The company’s 50-day simple moving average is $10.70 and its 200 day simple moving average is $9.79. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. On average, equities research analysts predict that Kura Oncology, Inc. will post -3.25 EPS for the current fiscal year.

Insider Activity at Kura Oncology

In other Kura Oncology news, CEO Troy Wilson acquired 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was acquired at an average price of $11.12 per share, with a total value of $1,112,000.00. Following the transaction, the chief executive officer owned 379,194 shares of the company’s stock, valued at approximately $4,216,637.28. This trade represents a 35.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brian T. Powl sold 17,020 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.53, for a total value of $179,220.60. Following the sale, the insider owned 152,249 shares of the company’s stock, valued at approximately $1,603,181.97. The trade was a 10.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 153,881 shares of company stock valued at $1,708,183. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc grew its stake in shares of Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after acquiring an additional 1,467 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 14.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company’s stock worth $175,000 after purchasing an additional 2,104 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Kura Oncology by 11.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock worth $194,000 after purchasing an additional 2,304 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in Kura Oncology by 842.5% during the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock worth $30,000 after purchasing an additional 2,519 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in Kura Oncology by 22.6% during the third quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock worth $154,000 after purchasing an additional 2,656 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.